Key Finding
A systematic appraisal of 15 RCTs and 10 systematic reviews found that the methodological quality of existing research on acupuncture for hot flashes and musculoskeletal symptoms in breast cancer patients is too poor to draw reliable conclusions about its effectiveness.
If you or someone you love has been through breast cancer treatment, you may have experienced frustrating side effects like hot flashes and joint pain. These symptoms are common during and after treatment, especially for those taking hormone-blocking medications. Many patients turn to acupuncture hoping for relief, and it's easy to understand why — acupuncture feels like a natural, gentle option that puts you in control of your health.
A new study published in the journal In Vivo took a close look at whether the existing research actually supports using acupuncture for these symptoms. Researchers searched five major medical databases in early 2025, gathering 15 clinical trials and 10 research summaries focused on hot flashes, plus 7 clinical trials and 9 research summaries focused on musculoskeletal symptoms like joint and muscle pain.
What they found was surprising — not because acupuncture failed, but because the studies themselves had serious quality problems. The researchers rated each study using established scientific tools and concluded that the overall quality of the research was poor. This means that even though there are many studies out there, we can't fully trust their results. The studies had design flaws that make it impossible to say with confidence whether acupuncture truly helps with hot flashes or joint pain in breast cancer patients.
This doesn't mean acupuncture doesn't work — it means we simply don't have solid proof yet either way. Many patients report feeling better after acupuncture, and personal experience matters. But science needs well-designed studies to confirm those benefits for everyone.
If you're considering acupuncture during or after breast cancer care, talk with your oncology team first, and look for a licensed acupuncturist with experience treating cancer patients.
This methodological review, published in In Vivo (2025), critically appraised the evidence base for acupuncture in managing menopausal symptoms — specifically hot flashes and musculoskeletal complaints — in breast cancer patients. Researchers searched five databases (Medline, CINAHL, EMBASE, Cochrane CENTRAL, PsycINFO) in February 2025. Fifteen RCTs and 10 systematic reviews addressing hot flashes were included, alongside 7 RCTs and 9 SRs addressing musculoskeletal symptoms. RCTs were assessed using the RoB 2 tool; SRs were evaluated with AMSTAR-2. Findings revealed predominantly poor methodological quality across both study types. No reliable effect sizes could be extracted due to high risk of bias in the RCTs and critically low AMSTAR-2 ratings in the SRs. The validity of SR conclusions is further compromised by their reliance on low-quality primary studies. Clinical takeaway: Despite a seemingly substantial body of literature, clinicians should not interpret existing RCTs or SRs as definitive evidence supporting acupuncture for menopausal symptom management in this population. Higher-quality primary research is urgently needed.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Heat-sensitive moxibustion combined with intrapleural cisplatin achieved a 65% clinical effective rate versus 30% for cisplatin alone, while also significantly reducing bone marrow suppression from 55% to 15% and gastrointestinal reactions from 65% to 30%.
📌 Traditional acupuncture reduced hot flash severity scores by an average of 1.89 points in breast cancer patients compared to just 0.16 points with sham acupuncture, a statistically significant difference (P=.0064) with effects sustained at one-month follow-up.
📌 Breast cancer survivors carrying at least one of six specific genotypes in genes related to thermoregulation and neurotransmission were significantly more likely to respond to acupuncture for hot flashes than non-carriers (70.3% vs. 37.5%, P=0.035), an association not seen with pharmacological treatment.